Commentary to the article of K. Kruczak and E. Ni? Ankowska-Mogilnicka: "The new diagnostic methods of latent tuberculosis infection";Komentarz do pracy K. Kruczak i E. Niżankowskiej-mogilnickiej: "nowe możliwości diagnostyki utajonego zakażenia prątkiem gruźlicy"

Pneumonologia i Alergologia Polska

Volumn 76, Issue 6, 2008, Pages 468-471

  Demkow, Urszula ^a  

^a Zak ad Diagnostyki Laboratoryjnej i Immunologii Klinicznej WUM   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BIOLOGICAL MARKER; CFP 10 PROTEIN, MYCOBACTERIUM TUBERCULOSIS; CFP-10 PROTEIN, MYCOBACTERIUM TUBERCULOSIS; ESAT 6 PROTEIN, MYCOBACTERIUM TUBERCULOSIS; ESAT-6 PROTEIN, MYCOBACTERIUM TUBERCULOSIS; GAMMA INTERFERON;

BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOLOGY; MYCOBACTERIUM TUBERCULOSIS; NOTE; STANDARD; TUBERCULIN TEST; TUBERCULOSIS;

ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERFERON-GAMMA; MYCOBACTERIUM TUBERCULOSIS; TUBERCULIN TEST; TUBERCULOSIS;

EID: 64549158942     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Kruczak K., Nizankowska-Mogilnicka E. Nowe możliwości diagnostyki utajonego zakażenia pra{ogonek}tkiem gruźlicy. Pneumonol. Alergol. Pol. 2008; 76: 446-450.
2. Kuś J. Gruźlica - sytuacja epidemiologiczna oraz współczesne pogla{ogonek}dy na leczenie i zapobieganie. Terapia i Leki 2002; 30//52/5-6: 26-29.
3. Roszkowski K., Szczuka I. Epidemiologia gruźlicy. Terapia 2004; 2: 57-58.
4. Broekmans J.F., Migliori G.B., Rieder H.L. European framework for tuberculosis control and elimination in countries with a low incidence. Eur. Respir. J. 2002; 19: 765-775.
5. Schwartzman K. Latent tuberculosis infection: old problem, new priorities. Candian Medical Association Journal 2002; 166: 756-761.
6. Mazurek G.H., LoBue P.A., Daley C.L., i wsp. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 2001; 286: 1740-1747.
7. Mazurek G.H., Villarino M.E. Guidelines for using the QuantiFERON- TB test for diagnosing latent Mycobacterium tuberculosis infection. Morb. Mortal. Wkly. Rep. Recomm. Rep. 2003; 52: 15-18.
8. Doherty T.M., Demissie A., Olobo J., i wsp. Immune responses to the Mycobacterium tuberculosis - specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J. Clin. Microbiol. 2002; 40: 704-706.
9. Styblo K. The relationship between the risk of tuberculosis infection and the risk of developing infectious disease. Bull. Int. Union Tubec. 1985; 60: 117-119.
10. Nienhaus A., Schablon A., Diel R. Interferon-gamma release assay for the diagnosis of latent TB infection - analysis of discordant results, when compared to the tuberculin skin test. PLoS ONE. 2008; 3: e2665.
11. Ruhwald M., Petersen J., Kofoed K., i wsp. Improving T-cell assays for the diagnosis of latent TB infection: potential of a diagnostic test based on IP-10. PLoS ONE. 2008; 3: e2858.
12. Leyten E.M., Arend S.M., Prins C., Cobelens F.G., Ottenhoff T.H., van Dissel J.T. Discrepancy between Mycobacterium tuberculosis - specific gamma interferon release assays using short and prolonged in vitro incubation. Clin. Vaccine Immunol. 2007; 14: 880-885.
13. Prevention and control of tuberculosis in correctional and detention facilities: recommendations from CDC. Endorsed by the Advisory Council for the Elimination of Tuberculosis, the National Commission on Correctional Health Care, and the American Correctional Association. MMWR Recomm. Rep. 2006; 55: 1-44.
14. Prevention Committee, Japan Tuberculosis Scientific Society. Kekkaku 2006; 81: 393-397.
15. Swiss Lung League. Detection of Latent Tuberculosis Using a Blood Test. Berna. Swiss Federal Office of Public Health 2005.
16. National Institute of Health and Clinical Excellence, www.nice.org.uk/CG033.
17. Diel R., Nienhaus A., Lange C., Meywald-Walter K., Forßbohm M., Schaberg T. Tuberculosis contact investigation with a new, specific blood test in a low-incidence population containing a high proportion of BCG-vaccinated persons. Respir Res. 2006; 7: 77.
18. Diel R., Nienhaus A., Lange C., Schaberg T. Cost-optimisation of screening for latent tuberculosis in close contacts. ERJ 2006; 28: 35-44.